Gonadotrophins probably leads to higher live birth rate per woman compared with continued clomiphene citrate (moderate certainty).
Gonadotrophins showed no clear difference in incidence of multiple pregnancy per woman compared with continued clomiphene citrate (moderate certainty).
Gonadotrophins probably leads to higher clinical pregnancy rate per woman compared with continued clomiphene citrate (moderate certainty).
Gonadotrophins may leads to higher miscarriages per woman compared with continued clomiphene citrate (low certainty).
It is very uncertain whether gonadotrophins changes live birth rate per couple randomly assigned compared with placebo/no treatment (very low certainty).
Gonadotrophins probably leads to higher spontaneous pregnancy rate per couple randomly assigned compared with placebo/no treatment (moderate certainty).
Gonadotrophins with anti‐oestrogens showed no clear difference in multiple pregnancy rate per couple compared with gonadotropins alone (low certainty).
It is very uncertain whether gonadotrophins with anti‐oestrogens changes clinical pregnancy rate per couple compared with gonadotropins alone (very low certainty).
Gonadotrophins with anti‐oestrogens showed no clear difference in OHSS rate per couple compared with gonadotropins alone (low certainty).
It is very uncertain whether LOD changes improvement in androgenic symptoms at 6 months (hirsutism/acne) ‐… compared with medical interventions (very low certainty).
LOD probably leads to lower harms: GI Upset at 6 months ‐ LOD vs metformin + clomiphene N of… compared with medical interventions (moderate certainty).
Recombinant follicle stimulating hormone showed no clear difference in live birth rate per woman compared with urinary‐derived gonadotrophins (low certainty).
Recombinant follicle stimulating hormone showed no clear difference in incidence of multiple pregnancy (per woman) compared with urinary‐derived gonadotrophins (low certainty).
Recombinant follicle stimulating hormone showed no clear difference in clinical pregnancy rate per woman compared with urinary‐derived gonadotrophins (low certainty).
Recombinant follicle stimulating hormone showed no clear difference in miscarriage rate per woman compared with urinary‐derived gonadotrophins (low certainty).
It is very uncertain whether recombinant follicle stimulating hormone changes incidence of OHSS per woman compared with urinary‐derived gonadotrophins (very low certainty).
The review found no eligible studies for this question.
Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only showed no clear difference in clinical pregnancy per woman compared with monitoring with TVUS plus serum estradiol (low certainty).